JP2004043482A - カルボン酸誘導体 - Google Patents
カルボン酸誘導体 Download PDFInfo
- Publication number
- JP2004043482A JP2004043482A JP2003284757A JP2003284757A JP2004043482A JP 2004043482 A JP2004043482 A JP 2004043482A JP 2003284757 A JP2003284757 A JP 2003284757A JP 2003284757 A JP2003284757 A JP 2003284757A JP 2004043482 A JP2004043482 A JP 2004043482A
- Authority
- JP
- Japan
- Prior art keywords
- group
- formula
- added
- lower alkyl
- solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- LELLMYXMIGNLBH-UHFFFAOYSA-N CC(C)(CCC(C)(C)c1c2)c1cc(CCC1C(C(OC)OC)c(cc3)ccc3C(OC)=O)c2C1=O Chemical compound CC(C)(CCC(C)(C)c1c2)c1cc(CCC1C(C(OC)OC)c(cc3)ccc3C(OC)=O)c2C1=O LELLMYXMIGNLBH-UHFFFAOYSA-N 0.000 description 1
- PVGCSQKEWGOAJH-UHFFFAOYSA-N CC(C)(CCC(C)(C)c1c2)c1cc1c2OC=CC1=O Chemical compound CC(C)(CCC(C)(C)c1c2)c1cc1c2OC=CC1=O PVGCSQKEWGOAJH-UHFFFAOYSA-N 0.000 description 1
- XIBPXTICLOAKSQ-UHFFFAOYSA-N CC(C)(CCC(C)(C)c1c2)c1cc1c2OCCC1=O Chemical compound CC(C)(CCC(C)(C)c1c2)c1cc1c2OCCC1=O XIBPXTICLOAKSQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/18—Ring systems of four or more rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
- C07D311/92—Naphthopyrans; Hydrogenated naphthopyrans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D335/08—Naphthothiopyrans; Hydrogenated naphthothiopyrans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
Abstract
【解決手段】一般式(III)で表される化合物またはそれらの生理的に認容性の塩。
[式中、環Dは次の式
{式中、R1及びR2はH、低級アルキル基等、またはR1とR2が一緒になって形成する、5〜7員のシクロアルキル環或いはこのシクロアルキル環を構成する炭素原子をS、O、N等で置き換えた複素環を示し、Ra及びRbはH、低級アルキル基等を示す}で表される基、Aは、O、S、NまたはCR4R5(R4、R5はHまたは低級アルキル基)等、Eは(CH2)n(式中nは0、1または2を示す)等、R12は、2個のHまたは次の式
(式中、R13、R14はHまたは低級アルキル基)で表される基から選ばれる一つの基である。]
【選択図】 なし
Description
Cell Biol.Rev.,25,209(1991) Proc.Natl.Acad.Sci.USA,89,7129(1992)
で表される基から選ばれる基を示す。〕
一般式(1)で表されるジケトン体は、ケトン体(2)に塩基の存在下、酸塩化物(3)を反応させ得ることができる。塩基としてはリチウムジイソプロピルアミド、リチウムビストリメチルシリルアミドなどがよい結果を与える。本反応の溶媒としてはジエチルエーテル、テトラヒドロフラン、1,2−ジメトキシエタンなどのエーテル類が用いられる。反応温度は−78℃〜溶媒の沸点であるが、好ましくは−78℃〜20℃である。
一般式(8)で示される化合物は、一般式(2)表されるケトン体に触媒量の塩基の存在下、一般式(9)で表されるアルデヒドを反応させて得られるアルコール体(10)を酸存在下で脱水反応させ得ることができる。アルコール体(10)を得るために用いられる塩基としては、水酸化ナトリウム、水酸化カリウムなどの水酸化アルカリが好ましく、溶媒にはメタノール、エタノール、プロパノール、テトラヒドロフラン、N,N−ジメチルホルムアミドなどを使用する。反応温度は0℃〜溶媒の沸点であるが、好ましくは20℃〜40℃である。
一般式(16)で示されるγ−ジケト化合物はケトン体(2)に塩基の存在下(17)の2−ハロアセトフェノンを反応させることにより得られる。塩基としてはリチウムジイソプロピルアミド、リチウムビストリメチルシリルアミドなどが好い結果を与える。本反応の溶媒としてはジエチルエーテル、テトラヒドロフラン、1,2-ジメトキシエタンなどのエーテル類が用いられる。反応温度は−78℃〜溶媒の沸点であるが、好ましくは−78℃〜室温である。
ケトン体(2)にN,N−ジメチルホルムアミドジメチルアセタールを作用させ、一般式(23)で表される化合物へと導くことができる。溶媒としてはベンゼン、トルエン、キシレンなどの芳香族炭化水素、N,N−ジメチルホルムアミド、ジメチルスルホキシドなどの非プロトン性溶媒、ジクロロメタン、クロロホルム、1,2−ジクロロエタンなどの塩素化炭化水素から適宜選択して使用する。反応温度は0℃〜溶媒の沸点である。
すなわち、一般式(40)で示されるカルボン酸体をポリリン酸中で直接還化させる。あるいは塩化チオニル、五塩化リンを用いて相応する酸塩化物に導いた後、塩化アルミニウム、四塩化チタン、塩化第二スズのようなルイス酸を加えて二硫化炭素、ジクロロメタンのような溶媒中、0℃〜溶媒の沸点の反応温度で得ることができる。
また、融点の測定には微量融点測定器(柳本製作所)を用いた。
・融点;131〜132℃
・1H−NMR(400MHz,CDCl3)δ(ppm);
1.30(s,6H),1.34(s,6H),1.70(s,4H),2.67〜2.80(m,4H),3.95(s,3H),
7.14(s,1H),7.63(d,J=8.4Hz, 2H),7.99(s,1H),8.12(d,J=8.4Hz,2H)
(2) 4−(4,5,7,8,9,10−ヘキサヒドロ−7,7,10,10−テトラメチルアントラ[2,1−d]ピラゾール−3−イル)安息香酸メチル
・融点;241〜243℃
・1H−NMR(400MHz,DMSO-d6)δ(ppm);
1.22(s,6H),1.26(s,6H),1.62(s,4H),2.80〜2.96(m,4H),3.85(s,3H),
7.24(s,1H),7.66(s,1H),7.84(d,J=8.4Hz,2H),8.02(d,J=8.4Hz,2H)
(3) 4−(1−エチル−4,5,7,8,9,10−ヘキサヒドロ−7,7,10,10−テトラメチルアントラ[2,1−d]ピラゾール−3−イル)安息香酸メチル
・融点;180〜181℃
・1H−NMR(400MHz,CDCl3)δ(ppm);
1.31(s,6H),1.33(s,6H),1.62(t,J=6.8Hz,3H),1.70(s,4H),2.90(s,4H),
3.93(s,3H),4.55(q,J=6.8Hz,2H),7.26(s,1H),7.48(s,1H),7.78(d,J=8.4Hz,2H),
8.10(d,J=8.4Hz,2H)
(4) 4−(1−エチル−4,5,7,8,9,10−ヘキサヒドロ−7,7,10,10−テトラメチルアントラ[2,1−d]ピラゾール−3−イル)安息香酸
・融点;278〜279℃
・1H−NMR(400MHz,DMSO-d6)δ(ppm);
1.23(s,6H),1.26(s,6H),1.47(t,J=6.8Hz,3H),1.64(s,4H),2.82(brs,4H),
4.50(q,J=6.8Hz,2H),7.33(s,1H),7.44(s,1H),7.77(d,J=8.4Hz,2H),
7.99(d,J=8.4Hz,2H)
(実施例2) 4−[4,5,7,8,9,10−ヘキサヒドロ−7,7,10,10−テトラメチル−1−(3−ピリジルメチル)アントラ[1,2−b]ピロール−3−イル]安息香酸
・融点;186〜187℃
・1H−NMR(400MHz,CDCl3)δ(ppm);
1.28(s,6H),1.32(s,3H),1.33(s,3H),1.75〜1,84(m,1H),1.98〜2.13(m,1H),
2.76〜2.92(m,3H),3.08(d,J=5.0Hz,1H),3.93(s,3H),5.70〜5.76(m,1H),
7.13(s,1H),7.45(d,J=8.4Hz,2H),8.02(s,1H),8.04(d,J=8.4Hz,2H)
4−(3,5,6,7,8−ペンタヒドロ−5,5,8,8−テトラメチル−1(4H)−アントラセノン−2−イリデン)安息香酸メチル
・融点;137℃
・1H−NMR(400MHz,CDCl3)δ(ppm);
1.30(s,6H),1.33(s,6H),1.70(s,4H),2.90(t,J=6.4Hz,2H),3.08(t,J=6.4Hz,2H),
3.93(s,3H),7.17(s,1H),7.48(d,J=8.4Hz,2H),7.81(s,1H),8.08(d,J=8.4Hz,2H),
8.10(s,1H)
4−[1−(3,4,5,6,7,8−ヘキサヒドロ−5,5,8,8−テトラメチル−1(2H)−アントラセノン−2−イル)−2,2−ジメトキシエチル]安息香酸メチル
・融点;282℃(分解)
・1H−NMR(400MHz,DMSO-d6)δ(ppm);
0.91(s,6H),1.17(s,6H),1.50(s,4H),2.68〜2.85(m,4H),5.58(s,2H),
6.90(s,1H),7.15(s,1H),7.34〜7.43(m,3H),7.53(d,J=8.4Hz,2H),
7.92(d,J=8.4Hz,2H),8.37(brs,1H),8.46(brs,1H)
参考例またはそれに準じて合成したケトン体を原料とし、実施例2と同様の手法により実施例3〜26の化合物を得た。
・融点;181〜184℃
・1H−NMR(400MHz,CDCl3)δ(ppm);
1.28(s,6H),1.30(s,6H),1.66(s,4H),2.77(t,J=8.0Hz,2H),
2.90(t,J=8.0Hz,2H),3.10(s,6H),7.06(s,1H),7.68(s,1H),7.99(s,1H)
4−(5,6,8,9,10,11−ヘキサヒドロ−8,8,11,11−テトラメチルアントラ[1,2−b]ピリジン−2−イル)安息香酸
・融点;267〜270℃
・1H−NMR(400MHz,DMSO-d6)δ(ppm);
1.26(s,6H),1.32(s,6H),1.64(s,4H),2.80〜2.98(m,4H),7.24(s,1H),
7.74(d,J=8.0Hz,1H),7.86(d,J=8.0Hz,1H),8.07(d,J=8.4Hz,2H),
8.28(d,J=8.4Hz,2H),8.30(s,1H)
次に、実施例で原料として使用した一般式
で表されるケトン体の合成を以下の参考例で示す。
・1H−NMR(400MHz,CDCl3)δ(ppm);
1.24(s,6H),1.25(s,6H),1.65(s,4H),3.36(s,1H),7.03(dd,J=8.9Hz,2.5Hz,1H),
7.17(d,J=8.9Hz,1H),7.22(d,J=2.5Hz,1H)
3−[2−(5,6,7,8−テトラヒドロ−5,5,8,8−テトラメチルナフチル)チオ]プロピオン酸
・融点;101℃
・1H−NMR(400MHz,CDCl3)δ(ppm);
1.24(s,6H),1.26(s,6H),1.66(s,4H),2.66(t,J=7.0Hz,2H),3.10(t,J=7.0Hz,2H),
7.14(dd,J=8.9,2.5Hz,1H),7.23(d,J=8.9Hz,1H),7.32(d,J=2.5Hz,1H)
3,5,6,7,8−ペンタヒドロ−5,5,8,8−テトラメチル−4−チア−1(2H)−アントラセノン
・融点;144〜145℃
・1H−NMR(400MHz,CDCl3)δ(ppm);
1.25(s,6H),1.26(s,6H),1.66(s,4H),2.94(t,J=9.0Hz,2H),3.20(t,J=9.0Hz,2H),
7.19(s,1H),8.08(s,1H)
(参考例2) 7,8,9,10−テトラヒドロ−7,7,10,10−テトラメチルナフト[2,3−b]シクロヘプタ−1−オン
・融点;117〜118℃
・1H−NMR(400MHz,CDCl3)δ(ppm);
1.28(s,6H),1.30(s,6H),1.70(s,4H),2.03〜2.13(m,2H),2.50(t,J=7.2Hz,2H),
3.04(t,J=7.2Hz,2H),7.38(d,J=8.8Hz,1H),7.70(dd,J=8.8Hz,2.5Hz,1H),
7.94(d,J=2.5Hz,1H)
5−[2−(5,6,7,8−テトラヒドロ−5,5,8,8−テトラメチルナフチル)]吉草酸
・1H−NMR(400MHz,CDCl3)δ(ppm);
1.25(s,6H),1.26(s,6H),1.60〜1.76(m,4H),1.66(s,4H),2.38(t,J=7.2Hz,2H),
2.57(t,J=7.2Hz,2H),6.92(dd,J=8.8,2.5Hz,1H),7.08(d,J=2.5Hz,1H),
7.20(d,J=8.8Hz,1H)
7,8,9,10−テトラヒドロ−7,7,10,10−テトラメチルナフト[2,3−b]シクロヘプタ−1−オン
・融点;102〜105℃
・1H−NMR(400MHz,CDCl3)δ(ppm);
1.28(s,12H),1.67(s,4H),1.76〜1.90(m,4H),2.66〜2.74(m,2H),
2.83〜2.92(m,2H),7.09(s,1H),7.71(s,1H)
(参考例3) 3,4,6,7,8−ペンタヒドロ−6,6−ジメチル−9−チア−1(2H)−アントラセノン
・融点;116〜117℃
・1H−NMR(400MHz,CDCl3)δ(ppm);
1.35(s,6H),1.96(t,J=9.0Hz,2H),2.78(t,J=7.0Hz,2H),3.04(t,J=9.0Hz,2H),
3.25(t,J=7.0Hz,2H),7.15(d,J=8.9Hz,1H),7.61(dd,J=8.9,2.5Hz,1H),
8.00(d,J=2.5Hz,1H)
4−[6−(4,4−ジメチルチオクロマニル)]酪酸
・融点;88〜89℃
・1H−NMR(400MHz,CDCl3)δ(ppm);
1.32(s,6H),1.93(t,J=9.0Hz,2H),2.05〜2.14(m,2H),2.59(t,J=8.8Hz,2H),
2.85(t,J=9.0Hz,2H),3.02(t,J=8.8Hz,2H),7.22(s,1H),7.75(s,1H)
(参考例4) 3,5,6,7,8,−ペンタヒドロ−5,5,8,8−テトラメチル−4−オキソ−1(2H)−アントラセノン
・融点;147〜149℃
・1H−NMR(400MHz,CDCl3)δ(ppm);
1.26(s,6H),1.28(s,6H),1.67(s,4H),3.00(brs,3H),3.18(brs,3H),
5.75(d,J=13.0Hz,1H),6.85(s,1H),7.59(s,1H),7.86(d,J=13.0Hz,1H),
13.44(s,1H)
5,6,7,8,−テトラヒドロ−5,5,8,8−テトラメチル−4−オキソ−1(4H)アントラセノン
・融点;161〜163℃
・1H−NMR(400MHz,CDCl3)δ(ppm);
1.32(s,6H),1.33(s,6H),1.73(s,4H),6.27(d,J=5.6Hz,1H),7.36(s,1H),
7.78(d,J=5.6Hz,1H),8.12(s,1H)
3,5,6,7,8−ペンタヒドロ−5,5,8,8−テトラメチル−4−オキソ−1(2H)−アントラセノン
・融点;100℃
・1H−NMR(400MHz,CDCl3)δ(ppm);
1.26(s,12H),1.66(s,4H),2.77(t,J=6.4Hz,2H),4.48(t,J=6.4Hz,2H),
6.89(s,1H),7.84(s,1H)
(参考例5) 3,4,5,6,7,8−ヘキサヒドロ−4,4,5,5,8,8−ヘキサメチル−1(2H)−アントラセノン
・融点;75℃
・1H−NMR(400MHz,CDCl3)δ(ppm);
1.21(s,6H),1.26(s,4H),1.27(s,6H),1.48〜1.56(m,2H),1.62〜1.73(m,3H),
1.65(s,4H),2.56(t,J=7.6Hz,2H),6.96(dd,J=8.8,2.5Hz,1H),
7.10(d,J=2.5Hz,1H),7.20(d,J=8.8Hz,1H)
1,2,3,4,5,6,7,8−オクタヒドロ−1,1,4,4,5,5−ヘキサメチルアントラセン
・融点;94〜95℃
・1H−NMR(400MHz,CDCl3)δ(ppm);
1.24(s,6H),1.25(s,12H),1.54〜1.80(m,4H),1.64(s,4H),
2.70(t,J=7.0Hz,2H),6.93(s,1H),7.22(s,1H)
3,4,5,6,7,8−ヘキサヒドロ−4,4,5,5,8,8−ヘキサメチル−1(2H)−アントラセノン
・融点;136〜138℃
・1H−NMR(400MHz,CDCl3)δ(ppm);
1.29(s,12H),1.36(s,6H),1.67(s,4H),1.97(t,J=7.0Hz,2H),
2.68(t,J=7.0Hz,2H),7.32(s,1H),7.96(s,1H)
(参考例6) 3,4,5,6,7,8−ヘキサヒドロ−5,5−ジメチル−8−オキソ−1(2H)−アントラセノン
・1H−NMR(400MHz,CDCl3)δ(ppm);
1.24(t,J=7.2Hz,3H),1.35(s,6H),1.83〜1.88(m,2H),3.24(t,J=7.2Hz,2H),
4.10〜4.21(m,2H),4.22〜4.28(m,2H),6.80(d,J=8.4Hz,1H),
7.71(dd,J=8.4,2.4Hz,1H),7.97(d,J=2.4Hz,1H)
γ−オキソ−6−(4,4−ジメチルクロマニル)酪酸
・融点;110〜112℃
・1H−NMR(400MHz,CDCl3)δ(ppm);
1.28(s,6H),1.82〜1.87(m,2H),2.77(t,J=7.2Hz,2H),3.26(t,J=7.2Hz,2H),
4.23〜4.28(m,2H),6.81(d,J=8.8Hz,1H),7.71(dd,J=8.8,2.4Hz,1H),
7.97(d,J=2.4Hz,1H)
4−[6−(4,4−ジメチルクロマニル)]酪酸
・1H−NMR(400MHz,CDCl3)δ(ppm);
1.32(s,6H),1.84(t,J=7.2Hz,2H),1.88〜1.94(m,2H),2.38(t,J=7.2Hz,2H),
2.59(t,J=7.2Hz,2H),6.70(d,J=8.8Hz,1H),6.88(dd,J=8,2.8Hz,1H),
7.04(d,J=2.8Hz,1H)
3,4,6,7,8,9−ヘキサヒドロ−5,5−ジメチル−8−オキソ−1(2H)−アントラセノン
・1H−NMR(400MHz,CDCl3)δ(ppm);
1.32(s,6H),1.83(t,J=7.0Hz,2H),2.06〜2.14(m,2H),2.58(t,J=7.0Hz,2H),
2.86(t,J=7.0Hz,2H),4.16(t,J=7.0Hz,2H),7.12(s,1H),7.43(s,1H)
(参考例7) 7,8,9,10−テトラヒドロ−7,7,10,10−テトラメチルナフト[2,3−b]−5−オキソ−シクロヘプタ−1−オン
・1H−NMR(400MHz,CDCl3)δ(ppm);
1.24(s,6H),1.26(s,6H),1.30(t,J=7.2Hz,3H),1.56(s,2H),1.66(s,2H),
4.00(d,J=6.0Hz,1H),4.66(s,J=6.0Hz,2H),6.22(dt,J=16,1.4Hz,1H),
6.69(dd,J=8.8,3.0Hz,1H),6.84(d,J=3.0Hz,1H),7.08(dt,J=16,4Hz,1H),
7.22(d,J=8.8Hz,1H)
4−[2−(5,6,7,8−テトラヒドロ−5,5,8,8−テトラメチルナフトキシ)]酪酸エチル
・1H−NMR(400MHz,CDCl3)δ(ppm);
1.22〜1.29(m,15H),2.68(s,4H),2.08〜2.16(m,2H),2.53(t,J=7.0Hz,2H),
3.99(t,J=7.0Hz,2H),4.16(q,J=7.2Hz,2H),6.71(dd,J=8.7,3.0Hz,1H),
6.84(d,J=3.0Hz,1H),7.24(d,J=8.7Hz,1H)
7,8,9,10−テトラヒドロ−7,7,10,10−テトラメチルナフト[2,3−b]−5−オキソ−シクロヘプタ−1−オン
・融点;124〜125℃
・1H−NMR(400MHz,CDCl3)δ(ppm);
1.26(s,12H),1.66(s,4H),2.12〜2.23(m,2H),2.86(t,J=7.0Hz,2H),
4.20(t,J=7.0Hz,2H),6.98(s,1H),7.74(s,1H)
(参考例8) 7−イソプロポキシ−6−イソプロピル−1−テトラロン
・融点;149〜150℃
1H−NMR(400MHz,CDCl3)δ(ppm);
1.25(d,J=6.5Hz,6H),2.06〜2.15(m,2H),2.63(t,J=7.0Hz,2H),
2.88(t,J=7.0Hz,2H),3.29〜3.38(m,1H),6.42(s,1H),7.05(s,1H),
7.63(s,1H)
7−イソプロポキシ−6−イソプロピル−1−テトラロン
1H−NMR(400MHz,CDCl3)δ(ppm);
1.21(d,J=6.5Hz,6H),1.33(d,J=6.5Hz,6H),2.06〜2.14(m,2H),
2.60(t,J=7.0Hz,2H),2.88(t,J=7.0Hz,2H),3.28〜3.38(m,1H),
4.62〜4.70(m,1H),7.03(s,1H),7.45(s,1H)
(参考例9) 7−(2,5−ジメチル−ピロロ−1−イル)−1−テトラロン
・融点;119〜120℃
1H−NMR(400MHz,CDCl3)δ(ppm);
2.03(s,6H),2.16〜2.24(m,2H),2.70(t,J=7.0Hz,2H),3.04(t,J=7.0Hz,2H),
5.89(s,2H),7.30(dd,J=8.9Hz,2.5Hz,1H),7.36(d,J=8.9Hz,1H),
7.88(d,J=2.5Hz,1H)
(参考例10) 6,8−ジイソプロピル−1−テトラロン
・融点;122〜123℃
1H−NMR(400MHz,CDCl3)δ(ppm);
1.21(d,J=6.5Hz,12H),2.78(t,J=7.0Hz,2H),2.90〜3.00(m,2H),
3.35(t,J=7.0Hz,2H),3.72(s,3H),7.52〜7.67(m,3H),7.83〜7.90(m,4H)
3−(3,5−ジイソプロピルベンゾイル)プロピオン酸メチル
1H−NMR(400MHz,CDCl3)δ(ppm);
1.26(d,J=6.5Hz,12H),2.76(t,J=7.0Hz,2H),2.88〜3.00(m,2H),
3.32(t,J=7.0Hz,2H),3.71(s,3H),7.28(d,J=2.4Hz,1H),7.65(d,J=2.4Hz,2H)
6,8−ジイソプロピル−1−テトラロン
1H−NMR(400MHz,CDCl3)δ(ppm);
1.22(d,J=6.5Hz,6H),1.26(d,J=6.5Hz,6H),2.02〜2.09(m,2H),
2.63(t,J=7.0Hz,2H),4.10〜4.20(m,1H),6.93(s,1H),7.17(s,1H)
Claims (5)
- 一般式(III)で表される化合物またはそれらの生理的に認容性の塩。
Aは、O、S、SO2、NR3(R3は前記の意味を示す。)またはCR4R5(R4、R5は同一または相異なる水素原子または低級アルキル基を意味する。)を示し、Eは(CH2)n(式中nは0、1または2を示す。)、CHCH3、C(CH3)2を示し、破線部分は単結合または二重結合を意味する。
R12の結合を示す破線は単結合または二重結合を示し、R12は、2個の水素原子または次の式
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003284757A JP3992666B2 (ja) | 1992-12-28 | 2003-08-01 | カルボン酸誘導体 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP35861692 | 1992-12-28 | ||
JP2345093 | 1993-01-20 | ||
JP2003284757A JP3992666B2 (ja) | 1992-12-28 | 2003-08-01 | カルボン酸誘導体 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP32151793A Division JP3476883B2 (ja) | 1992-12-28 | 1993-12-21 | ヘテロ環含有カルボン酸誘導体 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2004043482A true JP2004043482A (ja) | 2004-02-12 |
JP3992666B2 JP3992666B2 (ja) | 2007-10-17 |
Family
ID=26360806
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP32151793A Expired - Fee Related JP3476883B2 (ja) | 1992-12-28 | 1993-12-21 | ヘテロ環含有カルボン酸誘導体 |
JP2003284757A Expired - Fee Related JP3992666B2 (ja) | 1992-12-28 | 2003-08-01 | カルボン酸誘導体 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP32151793A Expired - Fee Related JP3476883B2 (ja) | 1992-12-28 | 1993-12-21 | ヘテロ環含有カルボン酸誘導体 |
Country Status (14)
Country | Link |
---|---|
US (1) | US5612356A (ja) |
EP (1) | EP0638071B1 (ja) |
JP (2) | JP3476883B2 (ja) |
KR (2) | KR0126300B1 (ja) |
CN (2) | CN1036920C (ja) |
AT (1) | ATE151418T1 (ja) |
CA (1) | CA2129846A1 (ja) |
DE (1) | DE69309670T2 (ja) |
DK (1) | DK0638071T3 (ja) |
ES (1) | ES2102195T3 (ja) |
FI (1) | FI943948A0 (ja) |
GR (1) | GR3024074T3 (ja) |
NO (1) | NO304687B1 (ja) |
WO (1) | WO1994014777A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020533328A (ja) * | 2017-09-07 | 2020-11-19 | タイワンジェ ファーマシューティカルズ カンパニー リミテッドTaiwanj Pharmaceuticals Co., Ltd. | ベンゼン縮合複素環誘導体およびその医薬組成物 |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW334423B (en) * | 1993-10-22 | 1998-06-21 | Hoffmann La Roche | Tricyclic 1-aminoethylpyrrole-derivatives |
RU2139281C1 (ru) * | 1993-11-30 | 1999-10-10 | Джи Ди Сирл энд Компани | Пиразолилзамещенный бензолсульфонамид или его фармацевтически приемлемая соль, фармацевтическая композиция, способ лечения от воспаления или связанного с воспалением заболевания |
US6492411B1 (en) | 1993-11-30 | 2002-12-10 | G. D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation |
US5466823A (en) | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
US6716991B1 (en) | 1993-11-30 | 2004-04-06 | G. D. Searle & Co. | Process for preparing a substituted pyrazolyl benzenesulfonamide for the treatment of inflammation |
FR2735371B1 (fr) * | 1995-06-19 | 1997-07-18 | Cird Galderma | Procede pour identifier des composes antagonistes des recepteurs rars |
US6008204A (en) | 1995-09-01 | 1999-12-28 | Allergan Sales, Inc. | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
US5776699A (en) * | 1995-09-01 | 1998-07-07 | Allergan, Inc. | Method of identifying negative hormone and/or antagonist activities |
US5952345A (en) | 1995-09-01 | 1999-09-14 | Allergan Sales, Inc. | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
HUP9902645A3 (en) * | 1996-03-18 | 1999-12-28 | Eisai Co Ltd | Fused-ring carboxylic acid derivatives |
FR2753627B1 (fr) * | 1996-09-20 | 2003-02-21 | Galderma Rech Dermatologique | Utilisation des inhibiteurs de l'activite de l'acide retinoique pour favoriser la cicatrisation |
US5728846A (en) * | 1996-12-12 | 1998-03-17 | Allergan | Benzo 1,2-g!-chrom-3-ene and benzo 1,2-g!-thiochrom-3-ene derivatives |
US5919970A (en) * | 1997-04-24 | 1999-07-06 | Allergan Sales, Inc. | Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity |
CA2304466A1 (en) | 1997-10-06 | 1999-04-15 | Basf Aktiengesellschaft | Indeno[1,2-c]pyrazole derivatives for inhibiting tyrosine kinase activity |
DE69818083T2 (de) | 1997-10-06 | 2004-07-08 | Abbott Gmbh & Co. Kg | INDENO[1,2-c]-,NAPHTHO[1,2-C]-UND BENZO[6,7]CYCLOHEPTA[1,2-c]PYRAZOLDERIVATE |
WO1999024024A2 (en) | 1997-11-12 | 1999-05-20 | F. Hoffmann-La Roche Ag | Treatment of t-helper cell type 2 mediated immune diseases with retinoid antagonists |
CA2343194A1 (en) * | 1998-09-30 | 2000-04-06 | Taisho Pharmaceutical Co., Ltd. | Substituted isoxazolylthiophene compounds |
US6521641B1 (en) | 1998-10-08 | 2003-02-18 | Allergan, Inc. | Male anti-fertility agents |
US6288099B1 (en) | 1998-12-04 | 2001-09-11 | American Home Products Corporation | Substituted benzofuranoindoles and indenoindoles as novel potassium channel openers |
AU4225500A (en) * | 1999-04-14 | 2000-11-14 | Allergan Sales, Inc. | Methods and compositions for the treatment and prevention of lung disease |
US6043381A (en) * | 1999-05-07 | 2000-03-28 | Allergan Sales, Inc. | Process for preparing substituted benzo[1,2-g]-chrom-3-ene, benzo[1,2-g]-thiochrom-3-ene and benzo[1,2-g]-1,2-dihydroquinoline derivatives |
WO2001068135A2 (en) * | 2000-03-14 | 2001-09-20 | The University Of Western Ontario | Compositions and methods for affecting osteogenesis |
US20020193403A1 (en) | 2001-05-03 | 2002-12-19 | Allergan Sales, Inc. | Methods of treating hyperlipidemia |
WO2003033671A2 (en) * | 2001-10-18 | 2003-04-24 | Bristol-Myers Squibb Company | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions |
US7105566B2 (en) | 2002-10-22 | 2006-09-12 | Allergan, Inc. | Methods of treatment during vascular procedures |
SG146683A1 (en) | 2003-09-17 | 2008-10-30 | Janssen Pharmaceutica Nv | Fused heterocyclic compounds as serotonin receptor modulators |
US20050261347A1 (en) * | 2003-10-24 | 2005-11-24 | Wyeth | Dihydrobenzofuranyl alkanamine derivatives and methods for using same |
US7435837B2 (en) * | 2003-10-24 | 2008-10-14 | Wyeth | Dihydrobenzofuranyl alkanamine derivatives and methods for using same |
DE602004019685D1 (de) | 2003-12-26 | 2009-04-09 | Allergan Inc | DISUBSTITUIERTE CHALCOGENOXIME MIT ANTAGONISTISCHER WIRKUNG AM RAR(Gamma)-RETINOIDREZEPTOR |
AR055054A1 (es) * | 2005-04-22 | 2007-08-01 | Wyeth Corp | Cristales formados de clorhidrato de (((2r)-7-(2,6-diclorofenil)-5-fluoro-2,3- dihidro-1-benzofurano-2-il) metil ) amina |
DK1937244T3 (en) | 2005-09-30 | 2018-10-29 | Io Therapeutics Llc | : CANCER TREATMENT WITH SPECIFIC RXR AGONISTS |
CA2651487A1 (en) | 2006-05-16 | 2007-11-29 | Vitae Pharmaceuticals, Inc. | Methods for treating chemotherapy and radiation therapy side effects |
MX2009010828A (es) | 2007-04-06 | 2009-10-29 | Neurocrine Biosciences Inc | Antagonistas del receptor de la hormona liberadora de gonadotropina y metodos relacionados con los mismos. |
WO2008124614A1 (en) | 2007-04-06 | 2008-10-16 | Neurocrine Biosciences, Inc. | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
ES2480994T3 (es) * | 2008-03-31 | 2014-07-29 | Genentech, Inc. | Compuestos de tipo benzopirano y benzoxepina inhibidores de PI3K y métodos de uso |
DK2483278T3 (da) * | 2009-09-28 | 2014-01-13 | Hoffmann La Roche | Benzoxazepin pi3k-inhibitorforbindelser og deres anvendelse i behandlingen af cancer |
ES2558742T3 (es) | 2009-09-28 | 2016-02-08 | F. Hoffmann-La Roche Ag | Compuestos inhibidores de PI3K de benzoxepina y métodos de uso |
RU2013114352A (ru) | 2010-09-15 | 2014-10-20 | Ф. Хоффманн-Ля Рош Аг | Азабензотиазолы, композиции и способы применения |
CN103562210B (zh) | 2011-03-21 | 2016-05-25 | 弗·哈夫曼-拉罗切有限公司 | 对pI3K 110δ具有选择性的苯并氧氮杂*化合物及使用方法 |
US20130190395A1 (en) | 2011-12-13 | 2013-07-25 | Dartmouth College | Autoimmune disorder treatment using rxr agonists |
US9475816B2 (en) | 2012-09-07 | 2016-10-25 | Takeda Pharmaceutical Company Limited | Substituted-1,4-dihydropyrazolo[4,3-b]indoles |
AR103598A1 (es) | 2015-02-02 | 2017-05-24 | Forma Therapeutics Inc | Ácidos bicíclicos[4,6,0]hidroxámicos como inhibidores de hdac |
JP6668362B2 (ja) | 2015-02-02 | 2020-03-18 | フォーマ セラピューティクス,インコーポレイテッド | Hdac阻害薬としての3−アルキル−4−アミド−二環式[4,5,0]ヒドロキサム酸 |
CN105061316B (zh) * | 2015-07-17 | 2017-12-22 | 苏州大学 | 稠环类化合物、制备方法和用途 |
JP6823071B2 (ja) | 2015-10-31 | 2021-01-27 | アイオー セラピューティクス インコーポレイテッド | Rxrアゴニストおよび甲状腺ホルモンの組み合わせを用いた神経系障害の治療 |
ES2898676T3 (es) | 2015-11-25 | 2022-03-08 | Io Therapeutics Inc | Agonistas selectivos de rar-alfa resistentes a CYP26 en el tratamiento del cáncer |
CN105418637A (zh) * | 2015-12-08 | 2016-03-23 | 彭冬青 | 一种治疗甲亢的药物组合物 |
KR20180121983A (ko) | 2016-03-10 | 2018-11-09 | 아이오 테라퓨틱스, 인크. | Rxr 작용제 및 갑상선 호르몬의 조합을 사용한 근육 질환의 치료 |
US10946001B2 (en) | 2016-03-10 | 2021-03-16 | Io Therapeutics, Inc. | Treatment of autoimmune diseases with combinations of RXR agonists and thyroid hormones |
AU2017278220C1 (en) | 2016-06-10 | 2022-10-13 | Io Therapeutics, Inc. | Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy |
US10555935B2 (en) | 2016-06-17 | 2020-02-11 | Forma Therapeutics, Inc. | 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors |
CN109485651B (zh) * | 2017-06-29 | 2021-02-02 | 广西师范大学 | 2,3-稠环吲哚啉衍生物及其制备方法和应用 |
JP2020526551A (ja) | 2017-07-13 | 2020-08-31 | アイオー セラピューティクス インコーポレイテッド | がん免疫治療法のための免疫調節物質と併せた免疫調節性レチノイド及びレキシノイド化合物 |
CA3073953A1 (en) | 2017-08-31 | 2019-03-07 | Io Therapeutics, Inc. | Rar selective agonists in combination with immune modulators for cancer immunotherapy |
AU2018335393A1 (en) | 2017-09-20 | 2020-04-02 | Io Therapeutics, Inc. | Treatment of disease with esters of selective RXR agonists |
US10966950B2 (en) | 2019-06-11 | 2021-04-06 | Io Therapeutics, Inc. | Use of an RXR agonist in treating HER2+ cancers |
US11939328B2 (en) | 2021-10-14 | 2024-03-26 | Incyte Corporation | Quinoline compounds as inhibitors of KRAS |
US11896558B2 (en) | 2021-12-07 | 2024-02-13 | Io Therapeutics, Inc. | Use of an RXR agonist and taxanes in treating Her2+ cancers |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3119819A (en) * | 1959-07-29 | 1964-01-28 | Ciba Geigy Corp | Intermediates for 18-o-alkyl-reserpic acid esters and related compounds |
GB1071124A (en) * | 1965-05-11 | 1967-06-07 | Biorex Laboratories Ltd | Derivatives of pyrazolo-[4',5'-b]-11-oxo-18ª‡- and 18ª‰-olean-12-en-30-oic acid |
FR2614618B1 (fr) * | 1987-04-30 | 1989-07-07 | Cird | Derives heterocycliques polycycliques, leur procede de preparation et leur utilisation en medecine humaine et veterinaire |
LU87040A1 (fr) * | 1987-11-04 | 1989-06-14 | Oreal | Esters aromatiques polycycliques d'antibiotiques macrolidiques et lincosamidiques,leur procede de preparation et compositions pharmaceutiques et cosmetiques les contenant |
DE3903993A1 (de) * | 1989-02-10 | 1990-08-16 | Basf Ag | Diarylsubstituierte heterocyclische verbindungen, ihre herstellung und arzneimittel daraus |
CA2029497C (en) * | 1989-11-08 | 2002-06-04 | Kunihiro Ninomiya (Deceased) | 4-acylaminopyridine derivative |
-
1993
- 1993-12-20 AT AT94903025T patent/ATE151418T1/de not_active IP Right Cessation
- 1993-12-20 KR KR1019940703030A patent/KR0126300B1/ko active
- 1993-12-20 US US08/295,636 patent/US5612356A/en not_active Expired - Fee Related
- 1993-12-20 WO PCT/JP1993/001841 patent/WO1994014777A1/en active IP Right Grant
- 1993-12-20 DE DE69309670T patent/DE69309670T2/de not_active Expired - Fee Related
- 1993-12-20 CA CA002129846A patent/CA2129846A1/en not_active Abandoned
- 1993-12-20 DK DK94903025.8T patent/DK0638071T3/da active
- 1993-12-20 EP EP94903025A patent/EP0638071B1/en not_active Expired - Lifetime
- 1993-12-20 ES ES94903025T patent/ES2102195T3/es not_active Expired - Lifetime
- 1993-12-21 JP JP32151793A patent/JP3476883B2/ja not_active Expired - Fee Related
- 1993-12-27 CN CN93121224A patent/CN1036920C/zh not_active Expired - Fee Related
-
1994
- 1994-08-26 NO NO934326A patent/NO304687B1/no not_active IP Right Cessation
- 1994-08-26 FI FI943948A patent/FI943948A0/fi unknown
- 1994-08-29 KR KR1019940703030A patent/KR950700258A/ko not_active IP Right Cessation
-
1997
- 1997-05-06 CN CN97111106A patent/CN1173497A/zh active Pending
- 1997-07-09 GR GR970401730T patent/GR3024074T3/el unknown
-
2003
- 2003-08-01 JP JP2003284757A patent/JP3992666B2/ja not_active Expired - Fee Related
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020533328A (ja) * | 2017-09-07 | 2020-11-19 | タイワンジェ ファーマシューティカルズ カンパニー リミテッドTaiwanj Pharmaceuticals Co., Ltd. | ベンゼン縮合複素環誘導体およびその医薬組成物 |
JP7296948B2 (ja) | 2017-09-07 | 2023-06-23 | ニューソアラ バイオファーマ カンパニー リミテッド | ベンゼン縮合複素環誘導体およびその医薬組成物 |
Also Published As
Publication number | Publication date |
---|---|
WO1994014777A1 (en) | 1994-07-07 |
FI943948A (fi) | 1994-08-26 |
NO304687B1 (no) | 1999-02-01 |
KR950700258A (ko) | 1995-01-16 |
KR0126300B1 (ko) | 1997-12-26 |
ES2102195T3 (es) | 1997-07-16 |
ATE151418T1 (de) | 1997-04-15 |
NO943165D0 (no) | 1994-08-26 |
EP0638071B1 (en) | 1997-04-09 |
JP3992666B2 (ja) | 2007-10-17 |
EP0638071A1 (en) | 1995-02-15 |
CA2129846A1 (en) | 1994-07-07 |
JPH06271545A (ja) | 1994-09-27 |
DK0638071T3 (da) | 1997-10-27 |
GR3024074T3 (en) | 1997-10-31 |
DE69309670T2 (de) | 1997-11-20 |
DE69309670D1 (de) | 1997-05-15 |
NO943165L (no) | 1994-10-25 |
JP3476883B2 (ja) | 2003-12-10 |
US5612356A (en) | 1997-03-18 |
FI943948A0 (fi) | 1994-08-26 |
CN1036920C (zh) | 1998-01-07 |
CN1173497A (zh) | 1998-02-18 |
CN1094052A (zh) | 1994-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3992666B2 (ja) | カルボン酸誘導体 | |
DE3834204C2 (ja) | ||
KR100228949B1 (ko) | 이환상 테트라하이드로 피라졸로피리딘 | |
KR910002583B1 (ko) | 피페라진 유도체 또는 이의 염, 이의 제조방법 및 활성 성분으로서 이를 함유하는 약제학적 조성물 | |
JPH10504836A (ja) | オルト置換芳香族エーテル化合物及び鎮痛のための薬剤組成物中へのこれらの使用 | |
HU219464B (hu) | Etinil szubsztituált kromán és tiokromán származékok és eljárás a vegyületek előállítására | |
WO1996013478A1 (fr) | Derive d'acide carboxylique mono ou polyenique | |
JPH05310672A (ja) | 新規な2−シアノ−3−ヒドロキシエナミド、それらの製造法、それらを含有する製薬組成物及びそれらの薬剤としての使用 | |
FI89908C (fi) | Trisubstituerade benzoesyramellanprodukter | |
JP2007513120A (ja) | ピロール化合物 | |
JP2023527498A (ja) | Stat阻害化合物および組成物 | |
JP4241970B2 (ja) | アミド結合を有するインドール誘導体、及びモノ又はジアザインドール誘導体 | |
JPH03223277A (ja) | ベンゾチオフェン誘導体 | |
JPS63165362A (ja) | 置換アミノチメル−5,6,7,8−テトラヒドロナフチルオキシ酢酸類、中間体類、それらの製造法および薬物におけるそれらの使用 | |
WO2001014384A1 (fr) | Derives dihydrobenzofuran tricycliques, leur procede de preparation et agents | |
WO1996005820A1 (fr) | Medicament contre l'hyperlipemie | |
KR960011392B1 (ko) | 티오펜 카복스아미드 화합물 및 이의 제조방법 | |
IL301686A (en) | Process for the preparation of 5-(1-CYANOCYLOPROPYL)-PYRIDINE-2-CARBOXYLIC amides and nitriles | |
US4906757A (en) | Process for the preparation of dextrorotatory 3-(3-pyridyl)-1H,3H-pyrrolo [1,2-c]-7-thiazolecarboxylic acid | |
US6403814B1 (en) | Method for synthesizing diaryl-substituted heterocyclic compounds, including tetrahydrofurans | |
US5712393A (en) | Derivatives of 2-aminobenzenesulphonic acid and of 2-aminobenzenesulphonyl chloride, their preparation and their use as synthetic intermediates | |
JP3907220B2 (ja) | 複素環含有化合物 | |
EP3091000A1 (en) | Synthetic process of carprofen | |
ITMI20012308A1 (it) | Processo per la preparazione dell'estere etilico dell'acido 4-(8-cloro-5,6-diidro-11h-benzo-5,67-cicloepta-1,2-b-piridin-11-ilidene)-1-piper | |
JP2549997B2 (ja) | 新規ハロケタール化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20060811 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070529 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070620 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20070717 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070724 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100803 Year of fee payment: 3 |
|
LAPS | Cancellation because of no payment of annual fees |